JOURNAVX (suzetrigine)

Journavx (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that is selectively expressed in peripheral pain-sensing neurons (nociceptors), where its role is to transmit pain signals (action potentials). Because this therapeutic drug blocks pain signals only found in the periphery, not in the brain, it provides effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids.

The twice-daily Journavx is approved for the treatment of adults with moderate-to-severe acute pain.

Recommended Dosage: The recommended starting dose of Journavx is 100 mg orally. This medication is available in a tablet formulation which should be swallowed whole – do not chew or crush the tablets. For optimal beginning dosage absorption, take at least one hour before or two hours after meals. Drinkable clear liquids are permitted during this time, including water, tea, apple juice, and broth, as well as black coffee. After your first dose, you may take 50mg of Journavx every twelve hours following twelve hours. These doses can be taken with or without food.

Medications that contain grapefruit should not be consumed during treatment. To achieve the best therapeutic outcome, this medication should be used for the least amount of time necessary. Treatment of acute pain that is rated as moderate to severe should not exceed 14 days of this medication. Doing so has not been studied.

• Taking Journavx alongside potent and moderate CYP3A inhibitors may raise the drug levels and lead to pronounced side effects. To avert the possibility of toxicity and medication side effects, patients should seek medical advice before using this therapeutic drug in conjunction with CYP3A-modulating drugs.
• Treatment with this medicine has the potential to affect other CYP3A substrates, either reducing their effectiveness or increasing the side effects experienced by the patient. Patients who take other medications that are known to be processed through CYP3A need to speak to their doctors regarding some dose changes to avoid a lack of efficacy or adverse side effects.
• Those who use hormonal contraception may find that certain aspects of Journavx’s effectiveness on lowering their birth control pills efficacy may antagonize the intended effects, thereby increasing the chances of unplanned pregnancies. Any patients on combined oral, injectable, or implant hormonal contraception should contact their clinician to use addictive non-hormonal contraceptive methods during treatment.
• Moderate and severe liver impaired patients may have an increased exposure to the drug resulting in more toxicity. This medicine has to be taken with caution since there is an increased risk of drug-induced liver injury and doubted hepatic safety. Therefore, liver function tests need to be administered periodically.
• Female patients on Journavx should be aware that their fertility is affected by this drug during therapy but it is a reversible effect. Women who are worried about getting pregnant in the future should speak to their physician regarding such concerns. Side effects of Journavx usage can include unintended pregnancies, so it is recommended that women of childbearing age who are receiving treatment continue to take the contraceptives during the treatment.

What documents are required to import JOURNAVX to India?

JOURNAVX (suzetrigine) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is JOURNAVX available in India?

JOURNAVX (suzetrigine tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Journavx in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

JOURNAVX can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of JOURNAVX (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Journavx 50 mg price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source JOURNAVX (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Journavx®?

Suzetrigine is a Generic Name for the trade name drug Journavx®.

What is the Manufacturer's Name of Journavx®?

Journavx® is manufactured by Vertex Pharmaceuticals.

Is Journavx approved by the FDA?

Yes, Journavx® is approved by the FDA. Date of first approval: January 30, 2025.

What is the dosage and form of Journavx® supplied?

Journavx is supplied in Tablets: 50 mg tablets for oral administration.

What are the most common side effects of Journavx® 50 mg Tablets?

The most common side effects of Journavx® 50 mg tablets are muscle spasms, pruritus, increased creatine phosphokinase, and rash.

How much does Journavx® 50 mg Tablet cost in India?

Prices of Journavx 50 mg tablets may fluctuate over time because of market dynamics and regulatory changes. To get the most recent and transparent Journavx 50 mg cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Journavx® 50 mg Tablets be available in SAARC countries?

Apart from Gulf countries, Journavx® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Journavx® Tablets in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Journavx® 50 mg Tablets online in India?

Yes, one can buy Journavx 50 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Journavx® oral tablets through legal channels.

What are the storage conditions of Journavx® 50 mg Tablets?

Store Journavx® 50 mg Tablets at 20°C to 25°C (68°F to 77°F). Short-term temperature variations between 15°C to 30°C (59°F to 86°F) are allowed. Keep in a dry place, away from moisture, heat, and direct sunlight.